Share this article
Share this article
FRANKLIN LAKES, N.J., May 13, 2021 /PRNewswire/ BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the industry s first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC.
The new claim allows laboratories and facilities to process self-collected samples via a BD diluent tube using the BD Onclarity™ HPV Assay on either the BD Viper™ LT or the BD COR™ System. The BD Viper™ LT is in use globally and the BD COR™ System, launched last year, is in use across Europe.
BD Onclarity™ HPV Assay 3-Well PCR Reagent Wells
KalVista Pharmaceuticals (KALV) Expands Senior Leadership Team with Appointment of Paul K Audhya, MD, MBA as Chief Medical Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Christopher Graybill Joins ARCA as Vice President, Clinical Development
May 05, 2021 16:05 ET | Source: ARCA biopharma, Inc. ARCA biopharma, Inc. Westminster, Colorado, UNITED STATES
WESTMINSTER, Colo., May 05, 2021 (GLOBE NEWSWIRE) ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Christopher Graybill, Ph.D., has joined ARCA as Vice President, Clinical Development.
Dr. Michael Bristow, ARCA’s President and Chief Executive Officer, commented, “We are delighted to welcome Christopher to ARCA as Vice President of Clinical Development. His over 14 years of experience in the biotechnology and medical device industries, supporting global clinical strategy, clinical trial planning and conduct, and other aspects of product development including in the cardiovascular space, will be a
Share this article
Share this article
BEDMINSTER, N.J., May 4, 2021 /PRNewswire/ Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, recently named Ernesto Aycardi, M.D., to the position of Chief Development Officer on April 26, and is welcoming Eslie Dennis, M.D., MBChB, FCP(SA) in the role of Chief Medical Officer today. These appointments come at a pivotal time for the company, as the North America region aims to realize the full potential of its existing commercial portfolio and compounds being investigated in the pipeline. In particular, the company is working on plans to advance KW-6356, a selective antagonist of adenosine A2A receptors, and KHK4083, an Anti-OX40 Fully Human Antibody, and is also collaborating with partner MEI Pharma to complete the pivotal study and shape a broader development program for zandelisib, a selective PI3Kδ inhibitor.
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K Audhya, MD, MBA as Chief Medical Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.